Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma



Status:Archived
Conditions:Cancer, Gastrointestinal
Therapuetic Areas:Gastroenterology, Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:May 2009
End Date:March 2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma


The ongoing study is a Phase II, open-label study to evaluate the efficacy of MBP-426 at a
dose of 170 mg/m2 in combination therapy in patients with second line metastatic gastric,
gastro-esophageal junction or esophageal adenocarcinoma.



We found this trial at
3
sites
Huntsman Cancer Hospital
Salt Lake City, Utah 84112
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Mary Crowley Medical Research Center
Dallas, Texas 75201
?
mi
from
Dallas, TX
Click here to add this to my saved trials
University of Texas M.D. Anderson Cancer Center
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials